ERBB2 and non-small cell lung carcinoma: Another level of complexity lies with patients whose cancer has oncogenic mutations, as highlighted in a recent study that pooled three cohorts of NSCLC patients (n = 4189 total) with oncogenic alterations, including KRAS, MET, RET, BRAF-V600E and non BRAF-V600E, ROS1, ALK, EGFR exon 20, HER2, and classical EGFR (exon 19 deletion and exon 21 L858R) [38].